Intervention

irinotecan

ClinicalTrials.gov intervention label

Clinical trials11

Recruiting0

Common conditions7

Lead sponsors shown8

Clinical trials

11 shown

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung CancerNCT03879798 · 2019-03-15

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung CancerNCT03613753 · 2018-06-01

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyNCT03933449 · 2016-12-29

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)NCT02564263 · 2015-12-01

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast CancerNCT02030678 · 2014-09-01

Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer TreatmentNCT02171325 · 2014-06-01

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerNCT00695292 · 2008-06-01

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerNCT00308529 · 2006-03-01

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerNCT00294931 · 2006-02-01

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00248482 · 2002-02-01

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung CancerNCT00387660 · 2001-10-01

Common conditions

Lung Cancer3 Small Cell Lung Cancer3 Carcinoma, Small Cell Lung2 Esophageal Carcinoma2 Esophagogastric Junction Carcinoma2 Small-cell Lung Cancer1 Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer1

Leading sponsors

SCRI Development Innovations, LLC3 Merck Sharp & Dohme LLC2 Barbara Ann Karmanos Cancer Institute1 Guangdong Association of Clinical Trials1 Liaoning Cancer Hospital & Institute1 Memorial Sloan Kettering Cancer Center1 ShengFa Su1 University of California, Davis1

Trial status mix

COMPLETED7

UNKNOWN3

TERMINATED1

Phase mix

PHASE29

PHASE32

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.